(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 20 October 2016- Actelion Ltd (SIX: ATLN) today announced its results for the first nine months of 2016. OPERATING HIGHLIGHTS Strong Opsumit (macitentan) trajectory and quarterly net new patient gains sustained Excellent US launch momentum for Uptravi (selexipag) - enhanced by launches in Germany and the Netherlands Uptravi (selexipag) approvals in Switzerland and Japan (by Nippon Shinyaku) in Q3 First all-oral combination therapy with ponesimod and dimethyl fumarate (Tecfidera) to be evaluated for patients with relapsing multiple sclerosis FINANCIAL HIGHLIGHTS Sales growing to CHF 1,785 million (+14% at CER) - New PAH products surpass...
↧